论文部分内容阅读
Anti-tumour necrosis factor α （anti-TNFα） therapyis an established treatment in inflammatory boweldisease. However, this treatment is associated withhigh costs and the possibility of severe adverse eventsrepresenting a true challenge for patients, clinici